A type of herbal decoction called Pulsatilla chinensis is used in the preparation of a medicine for treating cognitive impairment.
Pulsatilla decoction and its active ingredient, Pulsatilla saponin B4, have addressed cognitive impairment associated with inflammatory bowel disease by improving cerebral blood flow and regulating neurotransmitter levels, achieving significant improvement in cognitive function and alleviating intestinal inflammation, and providing central protective effects.
Patent Information
- Application Number
- CN202610570738.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-04-28
- Publication Date
- 2026-07-10
AI Technical Summary
There are no reports on whether Pulsatilla chinensis decoction can improve cognitive impairment associated with inflammatory bowel disease or its application in the preparation of drugs for treating cognitive impairment.
Using Pulsatilla decoction and its active ingredient Pulsatilla saponin B4, cognitive impairment associated with inflammatory bowel disease is treated by improving cerebral blood flow, reducing hippocampal tissue damage, and regulating neurotransmitter levels in the brain.
It significantly improves spatial learning and memory, recognition and memory, and anxiety-depression-like behavior in model mice, increases cerebral blood flow, reduces hippocampal neuronal damage, and effectively regulates neurotransmitter levels in the brain, showing good prospects for clinical translation.
Smart Images

Figure CN122351352A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of natural product application technology, and in particular to the application of Pulsatilla chinensis decoction in the preparation of drugs for treating cognitive impairment. Background Technology
[0002] Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory disease affecting the digestive tract, primarily including ulcerative colitis (UC) and Crohn's disease (CD). In recent years, clinical studies have found that IBD patients often experience varying degrees of cognitive impairment, manifesting as decreased learning and memory abilities, poor concentration, and impaired executive function, severely impacting their quality of life. Epidemiological surveys show that the incidence of IBD-related cognitive impairment is significantly higher than in the general population, but its pathogenesis is not fully understood. Currently, it is believed to be related to factors such as chronic systemic inflammation, gut-brain axis disruption, neuroinflammation, and changes in cerebral hemodynamics.
[0003] Bai Tou Weng Tang, originating from the *Shang Han Lun* (Treatise on Cold Damage), is a classic Chinese medicine formula composed of four herbs: Pulsatilla chinensis, Coptis chinensis, Phellodendron chinense, and Fraxinus chinensis. It is used to treat damp-heat dysentery (equivalent to ulcerative colitis) and has the effects of clearing heat and detoxifying, cooling the blood and stopping dysentery. Modern pharmacological studies have shown that Bai Tou Weng Tang and its active ingredients (such as Pulsatilla saponin B4) have anti-inflammatory, antioxidant, and immunomodulatory effects. However, whether Bai Tou Weng Tang can improve IBD-related cognitive impairment, and its application in the preparation of drugs for treating cognitive impairment, has not yet been reported.
[0004] In summary, there are currently no reports on whether Pulsatilla chinensis decoction can improve IBD-related cognitive impairment, or its application in the preparation of drugs for treating cognitive impairment. Summary of the Invention
[0005] Therefore, the purpose of this invention is to provide an application of Pulsatilla chinensis decoction in the preparation of a drug for treating cognitive impairment, so as to overcome the shortcomings of the prior art.
[0006] This invention provides the application of Pulsatilla chinensis decoction in the preparation of drugs for treating cognitive impairment.
[0007] Furthermore, the cognitive impairment is a cognitive impairment associated with inflammatory bowel disease.
[0008] Furthermore, the cognitive impairments include spatial learning and memory impairment, recognition and memory impairment, anxiety-like behavior, and / or depression-like behavior.
[0009] Furthermore, the drug is used to improve at least one of the following: a)-c) a) Cerebral blood flow; b) Reduce hippocampal tissue damage; c) Regulate the level of neurotransmitters in the brain.
[0010] Furthermore, the neurotransmitter is selected from at least one of the following: a)-h) a) Tryptophan; b) 5-HT; c) Histidine; d) Histamine; e) Dopamine; f) GABA; g) Acetylcholine; h) Corticosterone.
[0011] Furthermore, the aforementioned Pulsatilla Decoction is made from Pulsatilla chinensis, Coptis chinensis, Phellodendron chinense, and Fraxinus chinensis.
[0012] Furthermore, the application of Pulsatilla saponin B4 in the preparation of drugs for treating cognitive impairment.
[0013] Furthermore, the cognitive impairment is a cognitive impairment associated with inflammatory bowel disease.
[0014] This invention discloses a novel application of Pulsatilla Decoction in the treatment of cognitive impairment, particularly cognitive impairment associated with inflammatory bowel disease. Experiments show that Pulsatilla Decoction significantly improves spatial learning and memory, recognition memory, and anxiety-depression-like behavior in model mice, while increasing cerebral blood flow, reducing hippocampal neuronal damage, and effectively regulating the levels of neurotransmitters such as tryptophan, 5-HT, dopamine, and GABA in the brain. This formula exerts a central protective effect while alleviating intestinal inflammation, demonstrating the dual regulatory advantage of the gut-brain axis. Furthermore, its active ingredient, Pulsatilla saponin B4, also improves cognitive function. This invention provides a scientific basis for the "repurposing" of classic formulas, possessing clear efficacy, good safety, and mature preparation technology, and has promising prospects for clinical translation. Attached Figure Description
[0015] Figure 1 The image shows the effect of Pulsatilla chinensis decoction in this invention on improving the symptoms of colitis in mice with IBD cognitive impairment; Figure 2 The figure shows the effects of Pulsatilla Decoction in this invention on the neurobehavior, cerebral blood flow, pathology, and neurotransmitters of mice with DSS-induced IBD cognitive impairment.
[0016] The following detailed description, in conjunction with the accompanying drawings, will further illustrate the present invention.
[0017] The embodiments of the present invention will be further described below with reference to the accompanying drawings. Detailed Implementation
[0018] Ten 7-week-old male C57BL / 6 mice, weighing (20±2) g, were housed in an SPF-grade environment (temperature 24±2℃, humidity 50%-60%) with free access to food and water. The mice were placed in a sleep deprivation device without initiating the deprivation program, allowing them to sleep freely for 15 consecutive days. An equal volume of physiological saline was administered by gavage daily.
[0019] Mice gain weight steadily ( Figure 1 A), DAI score is 0 ( Figure 1 B), the colon is approximately 8.2 cm long ( Figure 1 CD), colonic H&E staining showed intact crypt structure and no inflammatory cell infiltration ( Figure 1 EF). In the open field experiment, the activity time in the central region was normal; the latency to find the platform in the Morris water maze was approximately 18.5 s, and the number of platform crossings was approximately 6.8; the new object recognition index was approximately 68%. Figure 2 A); The correct arm of the Y maze takes approximately 52.3 seconds to enter. Figure 2 B); the forced swimming immobility time was approximately 35.2 s ( Figure 2 C). Laser speckle imaging showed cerebral blood flow of approximately 520 PU ( Figure 2 D, F). H&E staining of the hippocampus showed that neurons were closely arranged and clearly layered. Figure 2 E, G). Brain levels of tryptophan, 5-HT, histidine, histamine, dopamine, and GABA are within normal ranges; acetylcholine and corticosterone levels are also within normal ranges. Figure 2 Western blotting showed extremely low expression of CD86 and iNOS, and abundant expression of Arg-1. Immunofluorescence revealed that CD86 and iNOS-positive cells were rare in the CA1 region of the hippocampus, while Arg-1-positive cells were abundant.
[0020] Ten 7-week-old male C57BL / 6 mice were used, and the feeding conditions were the same as in Example 1. Sleep deprivation was used to establish the model: the mice were deprived of sleep for 20 hours daily for 15 consecutive days using a sleep deprivation device at 5 rpm, alternating directions every 3 rotations with an 18-second interval. After successful model establishment, the mice were administered an equal volume of physiological saline by gavage daily for 14 consecutive days.
[0021] Compared with the control group, the body weight of mice in the model group decreased significantly to 78.5% of the initial weight. Figure 1 A), DAI score rises to 4.8 ( Figure 1 B), the length of the colon is shortened to approximately 4.5 cm ( Figure 1 CD), colonic H&E staining showed crypt structure destruction and extensive inflammatory cell infiltration, pathological score 12.5 ( Figure 1EF). In the open field experiment, the activity time in the central region was significantly reduced; in the Morris water maze, the latency to find the platform increased to approximately 58.2 s, and the number of platform crossings decreased to approximately 1.2 times; the new object recognition index dropped to approximately 22% ( ). Figure 2 A); The correct arm entry time in the Y maze is reduced to approximately 18.5 s ( Figure 2 B); the forced swimming immobility time was extended to approximately 85.6 s ( Figure 2 C). Cerebral blood flow decreased to approximately 210 PU ( Figure 2 D, F). H&E staining of the hippocampus showed disordered neuronal arrangement, cell shrunkenness, and significant vacuolar degeneration. Figure 2 E, G). The concentrations of tryptophan, 5-HT, histidine, histamine, dopamine, and GABA in the brain were all significantly decreased, while the concentrations of acetylcholine and corticosterone were significantly increased. Figure 2 Western blotting showed significantly increased expression of CD86 and iNOS, and significantly decreased expression of Arg-1. Immunofluorescence showed a large increase in CD86 and iNOS-positive cells and a significant decrease in Arg-1-positive cells in the CA1 region of the hippocampus.
[0022] Ten 7-week-old male C57BL / 6 mice were used, and the modeling method was the same as in Example 2. After successful modeling, the mice were administered 1.25 g of raw Bai Tou Weng Decoction (composed of Bai Tou Weng, Huang Lian, Huang Bai, and Qin Pi in a weight ratio of 2:3:3:3) by gavage daily for 14 consecutive days.
[0023] Compared with the model group, the trend of weight loss in mice in the low-dose Pulsatilla chinensis decoction group was alleviated. Figure 1 A), DAI score dropped to 3.2 ( Figure 1 B), the colon length returned to approximately 5.8 cm ( Figure 1 CD), reduced colonic pathological damage ( Figure 1 EF). Behavioral tests showed that the new object recognition index improved to approximately 38% (P<0.05). Figure 2 A); The correct arm entry time in the Y maze is extended to approximately 30.2 seconds. Figure 2 B); the forced swimming immobility time was shortened to approximately 65.3 s ( Figure 2 C); Cerebral blood flow increased to approximately 310 PU ( Figure 2 D, F). H&E staining of the hippocampus showed that the neuronal arrangement was more regular and the number of vacuoles was reduced compared to the model group. Figure 2 E, G). Elevated levels of 5-HT, dopamine, and GABA in the brain, and decreased levels of corticosterone. Figure 2 Western blotting showed decreased expression of CD86 and iNOS, and increased expression of Arg-1. Immunofluorescence showed a decrease in CD86 and iNOS-positive cells and an increase in Arg-1-positive cells in the CA1 region of the hippocampus.
[0024] Ten 7-week-old male C57BL / 6 mice were used, and the modeling method was the same as in Example 2. After successful modeling, the mice were administered 2.5 g of raw Pulsatilla chinensis decoction per kg body weight by gavage daily for 14 consecutive days.
[0025] Compared with the model group, the mice in the medium-dose group of Pulsatilla chinensis decoction showed significant recovery in body weight. Figure 1 A), the DAI score dropped to 2.1 (P<0.01, Figure 1 B), the colon length returned to approximately 6.8 cm ( Figure 1 CD), colon pathology score significantly improved ( Figure 1 EF). All behavioral indicators showed significant improvement: the new object recognition index increased to approximately 52% (P<0.01, Figure 2 A); The correct arm entry time in the Y maze is extended to approximately 42.5 s ( Figure 2 B); the forced swimming immobility time was shortened to approximately 48.2 s ( Figure 2 C); Cerebral blood flow increased to approximately 415 PU (P<0.01, Figure 2 D, F). Damage to hippocampal neurons was significantly reduced, and they were more tightly packed. Figure 2 E, G). Brain levels of 5-HT, dopamine, and GABA were significantly elevated, while corticosterone was significantly decreased. Figure 2 Western blotting showed significantly decreased expression of CD86 and iNOS, and significantly increased expression of Arg-1. Immunofluorescence showed a decrease in M1 markers and an increase in M2 markers.
[0026] Ten 7-week-old male C57BL / 6 mice were used, and the modeling method was the same as in Example 2. After successful modeling, the mice were administered Pulsatilla chinensis decoction at a dose of 5.0 g of raw herb per kg of body weight by gavage for 14 consecutive days.
[0027] Compared with the model group, the body weight of mice in the high-dose Pulsatilla chinensis decoction group basically returned to normal. Figure 1 A), the DAI score dropped to 1.2 (P<0.001, Figure 1 B), the colon length returned to approximately 7.6 cm ( Figure 1 CD), the crypt structure is basically normal ( Figure 1 EF). The most significant improvements were observed in behavioral indicators: the new object recognition index increased to approximately 62% (P<0.001). Figure 2 A); The correct arm entry time in the Y maze is extended to approximately 48.5 s ( Figure 2 B); the forced swimming immobility time was shortened to approximately 40.2 s ( Figure 2 C); Cerebral blood flow increased to approximately 490 PU, close to the control group (P<0.001, Figure 2 D, F). Hippocampal neurons were arranged almost identically to the blank group, with no vacuolar degeneration ( Figure 2E, G). Brain levels of tryptophan, 5-HT, histidine, histamine, dopamine, and GABA recovered to near-blank levels, while acetylcholine and corticosterone decreased to blank levels. Figure 2 Western blotting showed that CD86 and iNOS expression decreased to near the control group, while Arg-1 expression increased significantly. Immunofluorescence showed that M1 markers were almost invisible, while M2 markers were widely distributed.
[0028] Ten 7-week-old male C57BL / 6 mice were used, and the modeling method was the same as in Example 2. After successful modeling, Pulsatilla saponin B4 was injected intraperitoneally daily at a dose of 10 mg / kg body weight for 14 consecutive days.
[0029] Compared with the model group, the body weight of mice in the Pulsatilla saponin B4 group was significantly restored. Figure 1 A), the DAI score dropped to 2.3 (P<0.01, Figure 1 B), the colon length returned to approximately 6.5 cm ( Figure 1 CD), colonic pathological damage significantly improved ( Figure 1 EF). Behavioral tests showed that the new object recognition index improved to approximately 50% (P<0.01). Figure 2 A); The correct arm entry time in the Y maze is extended to approximately 40.5 s ( Figure 2 B); the forced swimming immobility time was shortened to approximately 50.3 s ( Figure 2 C); Cerebral blood flow increased to approximately 400 PU (P<0.01, Figure 2 D, F). Significant improvement in hippocampal neuronal damage and reduced inflammatory cell infiltration (D, F). Figure 2 E, G). Brain levels of 5-HT, dopamine, and GABA were significantly elevated, while corticosterone was significantly decreased. Figure 2 Western blot analysis showed significantly decreased expression of CD86 and iNOS, and significantly increased expression of Arg-1. Immunofluorescence results were comparable to those of the medium-dose group of Pulsatilla chinensis decoction.
[0030] Ten 7-week-old male C57BL / 6 mice were used, and the modeling method was the same as in Example 2. After successful modeling, piracetam 200 mg / kg body weight was administered by gavage daily for 14 consecutive days.
[0031] Compared with the model group, the novel object recognition index of mice in the piracetam group increased to approximately 45% (P<0.05). Figure 2 A); The correct arm entry time in the Y maze is extended to approximately 36.5 s ( Figure 2 B); the forced swimming immobility time was shortened to approximately 55.6 s ( Figure 2 C); Cerebral blood flow increased to approximately 280 PU (P<0.05, Figure 2 D, F). Partial improvement in hippocampal neuronal damage ( Figure 2 E, G). Levels of 5-HT, dopamine, and GABA in the brain are elevated to some extent. Figure 2 H). Western blot showed no significant changes in CD86 and iNOS, but a slight increase in Arg-1. Immunofluorescence showed that M1 markers remained abundant. However, piracetam did not significantly improve intestinal inflammatory markers (body weight, DAI score, colon length, colon pathology). Figure 1 (AF) indicates that piracetam only improves some cognitive behaviors, cannot alleviate intestinal inflammation, and does not have a dual "gut-brain" regulatory effect.
[0032] In summary, the above embodiments fully demonstrate that Pulsatilla Decoction and its active ingredient Pulsatilla saponin B4 can effectively improve IBD-related cognitive impairment and relieve intestinal inflammation, which is superior to existing cognitive impairment treatments.
[0033] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are specific and detailed, they should not be construed as limiting the scope of the present invention. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these modifications and improvements all fall within the scope of protection of the present invention. Therefore, the scope of protection of this patent should be determined by the appended claims.
Claims
1. Application of Pulsatilla Decoction in the preparation of drugs for treating cognitive impairment.
2. The application according to claim 1, characterized in that, The cognitive impairment referred to is cognitive impairment associated with inflammatory bowel disease.
3. The application according to claim 1 or 2, characterized in that, The cognitive impairments include spatial learning and memory impairment, recognition and memory impairment, anxiety-like behavior, and / or depression-like behavior.
4. The application according to claim 3, characterized in that, The drug is used to improve at least one of the following: a)-c) a) Cerebral blood flow; b) Reduce hippocampal tissue damage; c) Regulate the level of neurotransmitters in the brain.
5. The application according to claim 4, characterized in that, The neurotransmitter is selected from at least one of the following: a)-h). a) Tryptophan; b) 5-HT; c) Histidine; d) Histamine; e) Dopamine; f) GABA; g) Acetylcholine; h) Corticosterone.
6. The application according to claim 1, characterized in that, The Bai Tou Weng Decoction is made from Bai Tou Weng (Pulsatilla chinensis), Huang Lian (Coptis chinensis), Huang Bai (Phellodendron chinense), and Qin Pi (Fraxinus chinensis).
7. Application of Pulsatilla saponin B4 in the preparation of drugs for treating cognitive impairment.
8. The application according to claim 7, characterized in that, The cognitive impairment referred to is cognitive impairment associated with inflammatory bowel disease.
